The King of Prussia-based company specializes in investigative research on patented, novel therapies that use parenteral administration for targeted rescue and chronic treatment of convulsive disorders, such as epilepsy and refractory epilepsy. Additionally, CRx Bio explores alternative therapeutic areas, including pain and targeted neurological encephalopathies, for both human and veterinary applications.